CN109715658B - 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 - Google Patents

可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 Download PDF

Info

Publication number
CN109715658B
CN109715658B CN201780049433.8A CN201780049433A CN109715658B CN 109715658 B CN109715658 B CN 109715658B CN 201780049433 A CN201780049433 A CN 201780049433A CN 109715658 B CN109715658 B CN 109715658B
Authority
CN
China
Prior art keywords
sfgfr3
polypeptide
seq
del4
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780049433.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109715658A (zh
Inventor
埃尔维雷·古兹
斯特凡妮·加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blue Coast University
French Institute Of Health And Medicine
Tera Sean Holdings Ltd
Therachon
Pfizer Inc
Original Assignee
Blue Coast University
French Institute Of Health And Medicine
Therachon
Universite de Nice Sophia Antipolis UNSA
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Coast University, French Institute Of Health And Medicine, Therachon, Universite de Nice Sophia Antipolis UNSA, Pfizer Inc filed Critical Blue Coast University
Publication of CN109715658A publication Critical patent/CN109715658A/zh
Application granted granted Critical
Publication of CN109715658B publication Critical patent/CN109715658B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780049433.8A 2016-07-07 2017-07-07 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 Expired - Fee Related CN109715658B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359607P 2016-07-07 2016-07-07
US62/359,607 2016-07-07
US201762467478P 2017-03-06 2017-03-06
US62/467,478 2017-03-06
PCT/EP2017/067119 WO2018007597A1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
CN109715658A CN109715658A (zh) 2019-05-03
CN109715658B true CN109715658B (zh) 2023-09-12

Family

ID=59381265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049433.8A Expired - Fee Related CN109715658B (zh) 2016-07-07 2017-07-07 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途

Country Status (20)

Country Link
US (3) US10294289B2 (https=)
EP (2) EP3481859B1 (https=)
JP (2) JP7046903B2 (https=)
KR (2) KR20220122762A (https=)
CN (1) CN109715658B (https=)
AU (2) AU2017294551B2 (https=)
BR (1) BR112019000257A2 (https=)
CA (1) CA3029877C (https=)
DK (1) DK3481859T3 (https=)
ES (1) ES2912559T3 (https=)
HU (1) HUE058734T2 (https=)
IL (1) IL264030A (https=)
MX (1) MX2018016257A (https=)
PL (1) PL3481859T3 (https=)
PT (1) PT3481859T (https=)
RU (1) RU2751483C2 (https=)
SG (1) SG11201900074WA (https=)
SI (1) SI3481859T1 (https=)
WO (1) WO2018007597A1 (https=)
ZA (1) ZA201900507B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7335247B2 (ja) * 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
US11625937B2 (en) * 2020-04-06 2023-04-11 Toyota Motor Engineering & Manufacturing North America, Inc. Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017198A2 (en) * 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
CN105121464A (zh) * 2013-01-16 2015-12-02 法国健康和医学研究院 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
WO1996041620A1 (en) 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgfr3 as a marker for mesenchymal skeletal progenitor cells
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU2002235202A1 (en) 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2083846B1 (en) 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
WO2014018673A2 (en) 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
EP3242888B8 (en) 2015-01-07 2021-06-02 Pfizer Inc. Soluble fgfr3 decoys for treating skeletal growth disorders
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7335247B2 (ja) 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017198A2 (en) * 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
CN105121464A (zh) * 2013-01-16 2015-12-02 法国健康和医学研究院 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FGFR3突变与软骨发育不全的研究进展;张明等;《中国优生与遗传杂志》;20101231;第18卷(第5期);全文 *

Also Published As

Publication number Publication date
CN109715658A (zh) 2019-05-03
US20210309718A1 (en) 2021-10-07
KR20220122762A (ko) 2022-09-02
RU2019100381A (ru) 2020-08-11
SI3481859T1 (sl) 2022-07-29
HUE058734T2 (hu) 2022-09-28
EP4122955A1 (en) 2023-01-25
US11697678B2 (en) 2023-07-11
JP2019527053A (ja) 2019-09-26
AU2017294551B2 (en) 2022-03-03
MX2018016257A (es) 2019-11-21
ES2912559T3 (es) 2022-05-26
EP3481859A1 (en) 2019-05-15
ZA201900507B (en) 2023-04-26
RU2751483C2 (ru) 2021-07-14
AU2022202906A1 (en) 2022-05-26
PT3481859T (pt) 2022-05-23
WO2018007597A1 (en) 2018-01-11
CA3029877A1 (en) 2018-01-11
AU2017294551A1 (en) 2019-01-31
DK3481859T3 (da) 2022-04-25
RU2019100381A3 (https=) 2020-11-23
US20180230197A1 (en) 2018-08-16
JP7046903B2 (ja) 2022-04-04
SG11201900074WA (en) 2019-02-27
KR20190037240A (ko) 2019-04-05
BR112019000257A2 (pt) 2019-10-01
KR102432192B1 (ko) 2022-08-12
CA3029877C (en) 2023-07-25
JP7348980B2 (ja) 2023-09-21
US20200190162A1 (en) 2020-06-18
EP3481859B1 (en) 2022-04-13
US10294289B2 (en) 2019-05-21
US11021528B2 (en) 2021-06-01
PL3481859T3 (pl) 2022-07-11
IL264030A (en) 2019-01-31
JP2022096660A (ja) 2022-06-29

Similar Documents

Publication Publication Date Title
CN109715658B (zh) 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途
ES2969528T3 (es) Mutantes de FGF21 y usos de los mismos
KR102668200B1 (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
JP7597398B2 (ja) 組換え神経成長因子のための組成物及び方法
US20210009657A1 (en) Soluble fgfr3 decoys for treating skeletal growth disorders
JP7335247B2 (ja) 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
WO2006029094A2 (en) Erythropoietin derivatives with altered immunogenicity
JP6820123B2 (ja) Ｃｃｌ３変異体を含む融合タンパク質およびその用途
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
HK40050674A (en) Soluble fgfr3 decoys for treating skeletal growth disorders
HK1246313B (en) Soluble fgfr3 decoys for treating skeletal growth disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200623

Address after: New York, USA

Applicant after: PFIZER Inc.

Applicant after: French Institute of Health and Medicine

Applicant after: Blue Coast University

Address before: Basel, Switzerland

Applicant before: Tera Sean Holdings Ltd.

Applicant before: French Institute of Health and Medicine

Applicant before: Blue Coast University

Effective date of registration: 20200623

Address after: Basel, Switzerland

Applicant after: Tera Sean Holdings Ltd.

Applicant after: French Institute of Health and Medicine

Applicant after: Blue Coast University

Address before: Fa Guowaerbang

Applicant before: THERACHON

Applicant before: French Institute of Health and Medicine

Applicant before: Blue Coast University

Effective date of registration: 20200623

Address after: Fa Guowaerbang

Applicant after: THERACHON

Applicant after: French Institute of Health and Medicine

Applicant after: Blue Coast University

Address before: Fa Guobiao

Applicant before: THERACHON

Applicant before: French Institute of Health and Medicine

Applicant before: University NICE SOPHIA ANTIPOLIS

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230912